Get the Stockscreener App
0.3788
3.19%
-0.0125
After Hours:
.38
0.0012
+0.32%
Sangamo Therapeutics Inc stock is traded at $0.3788, with a volume of 2.22M.
It is down -3.19% in the last 24 hours and down -15.63% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.3913
Open:
$0.396
24h Volume:
2.22M
Relative Volume:
0.32
Market Cap:
$140.79M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.5051
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
+7.16%
1M Performance:
-15.63%
6M Performance:
-26.80%
1Y Performance:
-66.48%
1-Day Range:
$0.3783
$0.4022
1-Week Range:
$0.3585
$0.41
52-Week Range:
$0.345
$1.2383
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.3788 | 145.44M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
FY2030 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics' (SGMO) Buy Rating Reiterated at HC Wainwright - MarketBeat
SGMO: HC Wainwright & Co. Maintains Buy Rating with $10 PT | SGM - GuruFocus
Assessing Sangamo Therapeutics (SGMO) Valuation After New Fabry Data Financing Move And Leadership Changes - simplywall.st
Sangamo starts FDA submission seeking approval of Fabry gene therapy - Fabry Disease News
Sangamo prices $25 million offering of common stock and warrants By Investing.com - Investing.com Nigeria
What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders - Sahm
Sangamo Biosciences launches dilutive February 2026 financing - TipRanks
Sangamo Therapeutics Signs Multiple Material Agreements - TradingView
Form 424B5 SANGAMO THERAPEUTICS, - StreetInsider
Sangamo To Present Positive Study Data Of ST-920 In Fabry Disease At WORLD Symposium 2026 - Nasdaq
Should FDA Accelerated Approval Pathway for ST-920 Gene Therapy Data Require Action From Sangamo Therapeutics (SGMO) Investors? - Yahoo Finance
Sangamo (SGMO) Appoints Interim CFO Amid Leadership Change - GuruFocus
Sangamo Therapeutics (SGMO) Price Target Increased by 17.31% to 3.89 - Nasdaq
Sangamo gene therapy shows positive kidney function results in Fabry disease - Investing.com India
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 - The Manila Times
Sangamo gene therapy shows positive kidney function results in Fabry disease By Investing.com - Investing.com South Africa
One-time Fabry gene therapy lifts kidney function in early trial data - Stock Titan
Sangamo Shares Fall After Pricing $25 Million Public Offering - marketscreener.com
Sangamo Therapeutics (SGMO) Stock Plummets 28% After $25M Offeri - GuruFocus
Sangamo stock plunges after pricing $25 million dilutive offering By Investing.com - Investing.com India
Sangamo Prices $250 Mln Offering; Stock Plunges - Nasdaq
Sangamo stock plunges after pricing $25 million dilutive offering - Investing.com
Sangamo plunges after pricing stock offering; principal financial officer exits - Seeking Alpha
Sangamo Therapeutics reports preliminary cash balance and CFO transition By Investing.com - Investing.com Nigeria
Sangamo Therapeutics to Raise $25 Million Through Public Offering of Common Stock - geneonline.com
Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com
Sangamo (SGMO) Appoints Nikunj Jain as Interim CFO - GuruFocus
Sangamo (SGMO) Announces New Stock Offering to Raise $25M - GuruFocus
Sangamo (SGMO) Reports Estimated Year-End Cash Holdings - GuruFocus
Sangamo Therapeutics slides after $25 million stock sale - TradingView
Sangamo Therapeutics Prices Underwritten Offering of Common Stock and Warrants, Expected to Raise Approximately $25 Million - Quiver Quantitative
Sangamo prices $25 million offering of common stock and warrants - Investing.com
Sangamo Therapeutics reports preliminary cash balance and CFO transition - Investing.com
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering - The Manila Times
Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stock's 29% Jump Looks Justified - 富途牛牛
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st
Analysts Expect Breakeven For Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Before Long - 富途牛牛
Sangamo Therapeutics (NASDAQ:SGMO) Downgraded by Wall Street Zen to Strong Sell - MarketBeat
Dow Update: Is Sangamo Therapeutics Inc a strong growth stock2025 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn
How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) - Yahoo Finance
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Aug Selloffs: Does Sangamo Therapeutics Inc have a sustainable dividendWeekly Stock Analysis & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Insider Sell: Whats the outlook for FRSXs sectorWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Does Sangamo Therapeutics Inc. have pricing powerEntry Point & Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
Published on: 2026-01-14 05:13:16 - Bộ Nội Vụ
Fabry Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart.com
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update - Finviz
10 Stocks Under $1 That Will Explode - Insider Monkey
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):